Atacicept
IgA Nephropathy (IgAN)
Key Facts
About Vera Therapeutics
Vera Therapeutics is advancing a pipeline of immunology-focused therapies, with its lead program, atacicept, showing promise in IgA nephropathy, a progressive kidney disease with high unmet need. The company's strategy centers on targeting B-cell and plasma cell pathways to address autoimmune conditions. With a Phase 2b/3 trial (ORIGIN) ongoing for atacicept in IgAN, Vera is positioned as a key player in the nephrology and immunology space, backed by experienced leadership and public market funding.
View full company profileAbout Vera Therapeutics
Vera Therapeutics is advancing a pipeline of immunology-focused therapies, with its lead program, atacicept, showing promise in IgA nephropathy, a progressive kidney disease with high unmet need. The company's strategy centers on targeting B-cell and plasma cell pathways to address autoimmune conditions. With a Phase 2b/3 trial (ORIGIN) ongoing for atacicept in IgAN, Vera is positioned as a key player in the nephrology and immunology space, backed by experienced leadership and public market funding.
View full company profileTherapeutic Areas
Other IgA Nephropathy (IgAN) Drugs
| Drug | Company | Phase |
|---|---|---|
| Sparsentan (FILSPARI™) | Travere Therapeutics | Approved |
| Telitacicept | Vor Biopharma | BLA Submitted |